Fragment 176-191

Fragment 176-191 is a synthetic peptide corresponding to the C-terminal region (amino acids 176–191) of human growth hormone (hGH). This 16-amino-acid sequence contains the lipolytic domain of the full hGH molecule and has been studied for its ability to stimulate fat breakdown (lipolysis) while avoiding many of the systemic effects associated with complete growth hormone, including insulin resistance, fluid retention, and tissue growth. The fragment is closely related to AOD-9604, which is a modified version of the 177-191 fragment with an added tyrosine residue and has undergone more extensive clinical investigation.

Mechanism of Action

The lipolytic activity of Fragment 176-191 is mediated through its interaction with the growth hormone receptor (GHR) on adipocytes. Full-length hGH exerts its fat-burning effects through a specific region of the molecule, and this region corresponds to the C-terminal fragment encompassing residues 176–191. When this fragment binds to GHR on fat cells, it activates intracellular signaling cascades that promote lipolysis — the breakdown of stored triglycerides into free fatty acids and glycerol for energy use.

The fragment also appears to inhibit lipogenesis — the conversion of non-fat substrates into stored body fat. Studies in genetically obese rodent models demonstrated that Fragment 176-191 reduced body weight and adipose tissue mass without the hyperglycemia or insulin resistance typically associated with exogenous growth hormone administration. This selectivity is thought to arise because the fragment activates GHR signaling pathways in adipocytes that are distinct from those activated in liver and muscle tissue by full-length hGH.

Research has also suggested that the fragment may influence glycogen synthase phosphatase activity in muscle tissue, potentially altering intracellular glycogen synthase concentrations. However, the primary research interest remains in its lipolytic selectivity — the ability to promote fat mobilization without the proliferative and metabolic side effects of complete growth hormone.

Pharmacokinetics

The pharmacokinetics of Fragment 176-191 have not been formally characterized in humans. Available data is limited to preclinical studies and inference from the closely related compound AOD-9604, which has undergone more extensive pharmacokinetic evaluation.

In preclinical models, the fragment demonstrates rapid absorption following subcutaneous injection, with peak plasma concentrations achieved within 1–2 hours. The peptide's small size (16 amino acids) makes it susceptible to proteolytic degradation by circulating peptidases, resulting in a relatively short systemic half-life. Estimated plasma half-life in rodents is on the order of minutes for the intact peptide, though active metabolites may contribute to observed biological effects.

The compound is typically administered subcutaneously in research settings. Some early studies explored oral administration, and while some activity was observed in rodent models, systemic bioavailability via the oral route is expected to be low for an unmodified peptide of this size. Intraperitoneal administration has been used extensively in preclinical studies and shows consistent lipolytic activity.

Distribution studies suggest the fragment reaches adipose tissue compartments, though detailed tissue distribution data in humans are not available. The absence of significant effects on blood glucose and IGF-1 levels in preclinical studies suggests the fragment does not engage GHR signaling in liver tissue to the same degree as full-length hGH.

Clinical Evidence

The preclinical evidence for Fragment 176-191 comes primarily from studies in genetically obese rodent models. Ng et al. demonstrated that administration of the fragment reduced body weight and adipose tissue mass in obese mice and rats, with effects observed at doses that did not elevate blood glucose or insulin levels. The fragment showed efficacy in reducing both subcutaneous and visceral fat depots.

It is important to note that the more robust clinical data exists for AOD-9604, the modified 177-191 fragment, which has undergone Phase I and Phase II clinical trials in humans. AOD-9604 demonstrated safety and preliminary efficacy for fat loss in overweight and obese human subjects. However, Fragment 176-191 itself has not been studied in controlled human clinical trials, and direct extrapolation from AOD-9604 data is limited by the structural differences between the two compounds.

The evidence grade of C reflects the existence of preclinical data and related clinical data from a closely related compound, but the absence of direct human clinical evidence for Fragment 176-191 specifically. Community-reported experiences provide additional context but cannot substitute for controlled trial data.

Community Experiences

The following testimonials are drawn from r/Peptides and r/Biohackers. Individual experiences vary. Nothing here constitutes medical advice.

"I used Fragment 176-191 for 8 weeks alongside a moderate caloric deficit and noticed significantly faster fat loss than with diet alone. My blood sugar stayed stable throughout, which was a big improvement over when I tried full GH." — r/Peptides user (reported 3.8 kg fat loss over 8 weeks)

"The targeted fat loss around my midsection was noticeable after about 3 weeks. No joint pain, no water retention — just steady fat loss while maintaining my training intensity." — r/Biohackers user (body recomposition protocol)

"I switched from AOD-9604 to Fragment 176-191 and found similar results at a lower cost. The fat loss was comparable and I didn't notice any difference in side effects." — r/Peptides user (reported using both compounds sequentially)

Frequently Asked Questions

Is Fragment 176-191 the same as AOD-9604? No. AOD-9604 is a modified version of the 177-191 fragment with an added tyrosine residue at the N-terminus. Fragment 176-191 is the unmodified 16-amino-acid sequence. They share similar lipolytic mechanisms but have different pharmacokinetic profiles and clinical development histories.

Does Fragment 176-191 affect blood sugar? In preclinical studies, the fragment did not significantly elevate blood glucose or insulin levels, which is one of its key advantages over full-length growth hormone. However, human data is limited, and individual responses may vary.

How does Fragment 176-191 compare to full growth hormone for fat loss? The fragment targets the lipolytic domain of hGH without engaging the full spectrum of growth hormone receptor signaling. This means it may promote fat loss without the fluid retention, joint pain, insulin resistance, and tissue growth effects associated with exogenous GH administration.

What is the typical dosing protocol? Community-reported dosing typically ranges from 250–500 mcg per day administered subcutaneously, often divided into 2–3 doses. Cycles of 4–8 weeks are common. These protocols are empirically derived and not based on controlled human pharmacokinetic data.

Compounds That Pair Well

• CJC-1295 / Ipamorelin — Growth hormone secretagogue combination that may complement the fragment's lipolytic effects by supporting natural GH pulsatility and metabolic function.
• AOD-9604 — A related HGH fragment with overlapping lipolytic activity that some researchers use in combination or sequential protocols.
• MOTS-c — A mitochondrial-derived peptide that supports metabolic flexibility and may enhance fat oxidation during caloric restriction.
• Tesamorelin — A GHRH analogue that specifically targets visceral adipose tissue through a complementary mechanism.
• 5-Amino-1MQ — An enzyme inhibitor that may support fat metabolism by blocking NNMT activity in adipose tissue.